Kasvu Therapeutics raises $34.4M series a

◆ Amount

$34.4M

◆ Announced

24 Sept 2026

◆ Company

◆ Source

◆ The Round

Kasvu Therapeutics raised $34.4M in series a funding, announced on 24 September 2026, led by Hadean Ventures, with participation from Tesi, Finnish Drug Discovery Center, Stephen Industries, Innovestor Life Science Fund, Nordic Science Investments, Helsinki University Funds. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.

◆ About Kasvu Therapeutics

Finnish biotech developing a TrkB-targeting small molecule antidepressant designed to replicate psychedelic neuroplasticity benefits without hallucinogenic effects. Kasvu Therapeutics is based in Finland and currently at series a stage, operating in Biotech.

◆ Investors

◆ Investing funds on Raise

• Nordic Science Investments

◆ Market context

Nordic Science Investments is profiled on Raise, Fusion42's database of venture funds — where each investor's thesis, cheque size and other tracked backings can be followed. This funding event is a citable node in Fusion42's market graph: it links Kasvu Therapeutics's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.

◆ Explore the market